ClinicalTrials.gg
TerminatedNCT05159388Updated Jun 16, 2026Results posted

A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors

A Phase 1/2 interventional study of PRS-344/S095012 in Solid Tumor, sponsored by Servier Bio-Innovation LLC. Terminated at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Servier Bio-Innovation LLC · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision to terminate during Phase 1

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Neoplasm Metastasis with a site in Australia — 60 open to participants now, 106 under way, 34 of them phase 3. Neoplasm Metastasis · Australia.

Enrollment
223rd of 253
46 · median 227
Started
2021
with 25 others
Phase 1/2
44 of 260
20 open now
Registered
181st of 260
by date

Among the 260 studies in Neoplasm Metastasis with a site in Australia, this one is the 223rd largest by enrollment of the 253 interventional ones that give a count, is one of 26 that started in 2021, is one of 44 in phase 1/2, and was the 181st registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

60 of the 260 studies in Neoplasm Metastasis with a site in Australia are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Neoplasm Metastasis with a site in Australia, or all of them as a file.
02

Study summary

This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors.

Read the detailed description

The trial is an open-label, multi-center safety trial of PRS-344/S095012. The trial consists of two parts, a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase 2)). The expansion part of the trial will be initiated once the optimal biological dose (OBD) has been determined. The study was terminated during phase 1 and thus, recruitment into phase 2 was not started.

03

Conditions studied

  • Solid Tumor

Browse trials for

Keywords

  • Solid Tumor = Phase 1/2
  • Open-label
  • Dose escalation
  • Metastatic
  • PRS-344
  • S095012
  • PRS-344/S095012
  • Anticalin protein
  • Bi-specific
  • 4-1BB
  • CD137
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years on the day the consent is signed.
  2. Patients with confirmed diagnosis of unresectable, locally advanced or solid tumor for which standard treatment options are not available, no longer effective, or not tolerated.
  3. Patient should have a documented disease progression on prior therapy before entry into this study.
  4. Patients must have at least one measurable target lesion as per 1.1.
  5. (ECOG) performance status of 0 or 1.
  6. Patient with no available archived material must have one or more tumor lesions amenable to .
  7. Adequate organ function as assessed by laboratory tests within 7 days prior to pretreatment with obinutuzumab.
  8. A female patient must use a highly effective method of during study treatment and for 120 days after last dose of PRS-344/S095012, or 18 months after the last obinutuzumab infusion, whichever comes the latest.

Exclusion criteria

Exclusion Criteria:

  1. Patients with previously treated may participate provided they are radiologically stable, clinically asymptomatic and are off therapies for at least 4 weeks. Low dose of \<10 mg/day prednisone or equivalent) is allowed.
  2. Patients who have received prior:

    1. Small molecule inhibitors, and/or other similar agent: ≤ 2 weeks or 5 half-lives, whichever is shorter.
    2. Chemotherapy, other monoclonal antibodies, antibody-drug conjugates, or other similar experimental therapies: ≤3 weeks or 5 half-lives, whichever is shorter.
    3. Radioimmunoconjugates or other similar experimental therapies ≤6 weeks or 5 half-lives, whichever is shorter.
  3. Patients who have received 4-1BB agonists in the past.
  4. Patients who had a major surgery within 4 weeks prior to first administration of IMP.
  5. History of progressive multifocal leukoencephalopathy.
  6. Active tuberculosis requiring treatment within 3 years prior to the start of treatment or a suspicion of latent tuberculosis by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    PRS-344/S095012

    PRS-344/S095012

    Drug: PRS-344/S095012

Interventions

  • DrugPRS-344/S095012

    PRS-344/S095012 Monotherapy or with pretreatment by obinutuzumab

06

What researchers measure

Primary outcomes

  1. Safety Measurements: Number of Participants With at Least One DLT in the First 28-days of Treatment

    Phase 1: Dose-limiting toxicities (DLTs) over the first 28-days of study treatment

    Time frame: 28 days

  2. Safety Measurements: Number of Participants With at Least One AE

    Phase 1: Adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0

    Time frame: Through study termination, approximately 3.5 years

  3. Safety Measurements: Number of Participants With at Least One AE Leading to Treatment Discontinuation

    Phase 1: Discontinuation of study treatment due to an AE

    Time frame: Through study termination, approximately 3.5 years

Secondary outcomes

  1. Mean PRS-344/S095012 Concentrations at the End of the Infusion

    Phase 1

    Time frame: Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle was 28 days)

  2. Mean PRS-344/S095012 Trough Concentrations (Ctrough)

    Phase 1

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 4 Day 1, Cycle 4 Day 15, Cycle 5 Day 1, Cycle 5 Day 15, Cycle 6 Day 1 (each cycle was up to 28 days)

  3. Number of Participants With at Least One Positive Anti-drug Antibody (ADA) Titer Result PRS-344/S095012

    Phase 1

    Time frame: Through study termination, approximately 3.5 years

  4. Objective Response Rate (ORR)

    Phase 1: Defined as Complete Response (CR) plus Partial Response (PR), per investigator assessment

    Time frame: Through study termination, approximately 3.5 years

  5. Best Overall Response (BOR)

    Phase 1: The best response across visits as; 1) partial response (PR): At least 2 PR or better (PR followed by PR or PR followed by CR) at least 4 weeks apart and not qualifying for a complete response (CR), 2) stable disease (SD): At least 1 SD assessment (or better) ≥ 43 days (assuming an 8-week scan interval with a 14-day visit window) after start of study treatment and not qualifying for CR or PR, 4) progressive disease (PD): Documentation of PD after start of study treatment (and not qualifying for CR, PR, or SD), 5) non-evaluable (NE): All other cases.

    Time frame: Through study termination, approximately 3.5 years

  6. Best Tumor Shrinkage From Baseline

    Phase 1: The best shrinkage value for the target lesion from baseline

    Time frame: Through study termination, approximately 3.5 years

07

Results

Posted Jun 16, 2026
Limitations and caveats
The Sponsor decided to prematurely discontinue recruitment to the CL1-95012-001 study because the overall benefit-risk balance of PRS-344/S095012 was unfavorable. The participants in Phase 1 were allowed to continue the FU until disease progression or any other reason to discontinue study treatment. The Phase 2 dose expansion of the study was not initiated.

Participant flow

Participant flow — Overall Study
MilestonePRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
Started4914613
Completed00020
Not completed4914413
Withdrew: Withdrawal of consent02011
Withdrew: Death due to progressive disease251226
Withdrew: Death due to other causes10212
Withdrew: Other12004

Outcome measures

PrimarySafety Measurements: Number of Participants With at Least One DLT in the First 28-days of Treatment

Phase 1: Dose-limiting toxicities (DLTs) over the first 28-days of study treatment

Time frame:
28 days
Reported as:
Count of participants · Participants
Safety Measurements: Number of Participants With at Least One DLT in the First 28-days of Treatment
ParticipantsPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
Safety Measurements: Number of Participants With at Least One DLT in the First 28-days of Treatment01313
PrimarySafety Measurements: Number of Participants With at Least One AE

Phase 1: Adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0

Time frame:
Through study termination, approximately 3.5 years
Reported as:
Count of participants · Participants
Safety Measurements: Number of Participants With at Least One AE
ParticipantsPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
Safety Measurements: Number of Participants With at Least One AE4914612
PrimarySafety Measurements: Number of Participants With at Least One AE Leading to Treatment Discontinuation

Phase 1: Discontinuation of study treatment due to an AE

Time frame:
Through study termination, approximately 3.5 years
Reported as:
Count of participants · Participants
Safety Measurements: Number of Participants With at Least One AE Leading to Treatment Discontinuation
ParticipantsPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
Safety Measurements: Number of Participants With at Least One AE Leading to Treatment Discontinuation14727
SecondaryMean PRS-344/S095012 Concentrations at the End of the Infusion

Phase 1

Time frame:
Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle was 28 days)
Reported as:
Mean · ng/mL
Mean PRS-344/S095012 Concentrations at the End of the Infusion
ng/mLPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
Cycle 1 Day 13703.3 ± 1627.210169.3 ± 1222.718843.0 ± 4836.722022.9 ± 3533.09884.4 ± 2245.4
Cycle 2 Day 12542.7 ± 1963.55927.5 ± 3534.78961.4 ± 10780.912292.2 ± 8914.18118.0 ± 2319.4
SecondaryMean PRS-344/S095012 Trough Concentrations (Ctrough)

Phase 1

Time frame:
Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 4 Day 1, Cycle 4 Day 15, Cycle 5 Day 1, Cycle 5 Day 15, Cycle 6 Day 1 (each cycle was up to 28 days)
Reported as:
Mean · ng/mL
Mean PRS-344/S095012 Trough Concentrations (Ctrough)
ng/mLPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
Cycle 1 Day 10.0 ± 0.00.0 ± 0.02.3 ± 8.60.0 ± 0.00.0 ± 0.0
Cycle 1 Day 150.0 ± 0.00.0 ± 0.02.5 ± 5.06.3 ± 6.264.7 ± 191.4
Cycle 2 Day 10.0 ± 0.00.9 ± 2.21.1 ± 3.20.0 ± 0.02.9 ± 7.1
Cycle 2 Day 150.0 ± 0.01.3 ± 2.90.0 ± 0.00.0 ± 0.00.0 ± 0.0
Cycle 3 Day 10.0 ± 0.03.0 ± 5.90.0 ± 0.00.00.0 ± 0.0
Cycle 3 Day 150.0 ± 0.00.0 ± 0.00.0 ± 0.00.00.0
Cycle 4 Day 10.0 ± 0.00.0 ± 0.00.0 ± 0.00.00.0 ± 0.0
Cycle 4 Day 150.0 ± 0.00.0 ± 0.00.0—0.0
Cycle 5 Day 1—0.0 ± 0.00.0—0.0
Cycle 5 Day 15—0.0 ± 0.00.0—0.0
Cycle 6 Day 10.0 ± 0.00.0 ± 0.00.0—0.0
SecondaryNumber of Participants With at Least One Positive Anti-drug Antibody (ADA) Titer Result PRS-344/S095012

Phase 1

Time frame:
Through study termination, approximately 3.5 years
Reported as:
Count of participants · Participants
Number of Participants With at Least One Positive Anti-drug Antibody (ADA) Titer Result PRS-344/S095012
ParticipantsPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
Number of Participants With at Least One Positive Anti-drug Antibody (ADA) Titer Result PRS-344/S095012381042
SecondaryObjective Response Rate (ORR)

Phase 1: Defined as Complete Response (CR) plus Partial Response (PR), per investigator assessment

Time frame:
Through study termination, approximately 3.5 years
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
Objective Response Rate (ORR)0 (0 to 49.0)0 (0 to 32.4)0 (0 to 21.5)0 (0 to 39.0)10.0 (1.8 to 40.4)
SecondaryBest Overall Response (BOR)

Phase 1: The best response across visits as; 1) partial response (PR): At least 2 PR or better (PR followed by PR or PR followed by CR) at least 4 weeks apart and not qualifying for a complete response (CR), 2) stable disease (SD): At least 1 SD assessment (or better) ≥ 43 days (assuming an 8-week scan interval with a 14-day visit window) after start of study treatment and not qualifying for CR or PR, 4) progressive disease (PD): Documentation of PD after start of study treatment (and not qualifying for CR, PR, or SD), 5) non-evaluable (NE): All other cases.

Time frame:
Through study termination, approximately 3.5 years
Reported as:
Count of participants · Participants
Best Overall Response (BOR)
ParticipantsPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
PR00001
SD43213
PD04835
NE02423
SecondaryBest Tumor Shrinkage From Baseline

Phase 1: The best shrinkage value for the target lesion from baseline

Time frame:
Through study termination, approximately 3.5 years
Reported as:
Mean · mm
Best Tumor Shrinkage From Baseline
mmPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
Best Tumor Shrinkage From Baseline104.5 ± 150.05102.5 ± 67.24115.3 ± 107.9178.3 ± 86.0594.1 ± 68.68

Adverse events

Collected over Through study termination, approximately 3.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PRS-344/S095012 12mg3/4 (75%)1/4 (25%)4/4 (100%)
PRS-344/S095012 36mg5/9 (55.6%)8/9 (88.9%)9/9 (100%)
PRS-344/S095012 60mg14/14 (100%)12/14 (85.7%)14/14 (100%)
PRS-344/S095012 80mg3/6 (50%)3/6 (50%)6/6 (100%)
PRS-344/S095012 36mg and Obinutuzumab8/13 (61.5%)11/12 (91.7%)12/12 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/42/95/140/64/12
Cytokine release syndromeImmune system disorders0/41/94/141/61/12
Drug-induced liver injuryHepatobiliary disorders0/40/90/140/63/12
Pleural effusionRespiratory, thoracic and mediastinal disorders1/40/92/140/60/12
Abdominal compartment syndromeGastrointestinal disorders0/40/90/141/60/12
Intestinal obstructionGastrointestinal disorders0/41/90/141/60/12
Multiple organ dysfunction syndromeGeneral disorders0/40/90/141/60/12
Hepatic failureHepatobiliary disorders0/41/90/141/61/12
Haemophagocytic lymphohistiocytosisImmune system disorders0/40/91/141/60/12
Bacterial sepsisInfections and infestations0/40/90/141/60/12
Most frequent other events
Showing 10 of 158
Most frequent other events
EventPRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and Obinutuzumab
DiarrhoeaGastrointestinal disorders3/41/93/141/60/12
NauseaGastrointestinal disorders0/42/93/144/65/12
FatigueGeneral disorders2/43/99/143/67/12
Abdominal painGastrointestinal disorders2/41/90/141/61/12
PyrexiaGeneral disorders1/43/97/141/63/12
Aspartate aminotransferase increasedInvestigations2/43/94/140/61/12
Night sweatsSkin and subcutaneous tissue disorders2/40/92/141/60/12
Infusion related reactionInjury, poisoning and procedural complications0/44/93/142/62/12
Decreased appetiteMetabolism and nutrition disorders0/41/94/141/65/12
Abdominal distensionGastrointestinal disorders0/41/91/142/60/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)PRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and ObinutuzumabTotal
Mean55.0 ± 10.1062.2 ± 8.8159.4 ± 14.6753.8 ± 8.8462.7 ± 13.2859.8 ± 12.21
Age, Customized
Age, Customized(Participants)PRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and ObinutuzumabTotal
<65 years3576728
≥65 years1470618
Sex: Female, Male
Sex: Female, Male(Participants)PRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and ObinutuzumabTotal
Female1593321
Male34531025
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)PRS-344/S095012 12mgPRS-344/S095012 36mgPRS-344/S095012 60mgPRS-344/S095012 80mgPRS-344/S095012 36mg and ObinutuzumabTotal
Count of participants—————0
08

Study locations

11 sites
  • Carolina Bio Oncology
    Huntersville, North Carolina 28078, United States
  • NEXT Oncology
    San Antonio, Texas 78229, United States
  • Cabrini Oncology Research
    Malvern, Victoria, Australia
  • Chris O'Brian Lifehouse
    Camperdown, Australia
  • The Queen Elizabeth Hospital
    Woodville South, Australia
  • Institute Jules Bordet
    Brussels, Belgium
  • Universitair Ziekenhuis
    Edegem, Belgium
  • U.Z. Gent Medical Oncology
    Ghent, Belgium
  • Hospital Vall d'Hebron
    Barcelona, Spain
  • START
    Madrid, 28050, Spain
  • Hospital Universitario Gregorio
    Madrid, Spain
09

References and documents

Publications

  • Jungels C, Kotecki N, Calvo E, Garralda E, Price T, Zahn X, Abbas A, Mahnke L, Rauschning W, Morales-Kastresana A, Lucia Pattarini L, Bossenmaier B, Scholer-Dahirel A, Demuth T, Legrande J. Abstract CT255: Study of PRS-344/S095012 a PD-L1/4-1BB bispecific antibody-Anticalin®-fusion in patients with solid tumors. Canc Res. 2022 Jun 15;82(12_Supplement):CT255. doi: https://doi.org/10.1158/1538-7445.AM2022-CT255

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Apr 2025, 42 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Dec 16, 2021
StartActual
Sep 8, 2021
Primary completionActual
Apr 1, 2025
CompletionActual
Apr 1, 2025
Results first posted
Jun 16, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05159388
Lead sponsor
Servier Bio-Innovation LLC
Collaborators
Institut de Recherches Internationales Servier
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Sep 8, 2021
Primary completion
Apr 1, 2025
Completion
Apr 1, 2025
Results posted
Jun 16, 2026
Last update
Jun 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion